Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.
Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.
Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.
